Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma

被引:3
|
作者
Zganjar, Andrew [1 ]
Khanna, Abhinav [1 ]
Joyce, Dan [1 ]
Nichols, Paige [1 ]
Britton, Cameron [1 ]
Lohse, Christine M. [2 ]
Cheville, John C. [3 ]
Gupta, Sounak [3 ]
Potretzke, Aaron M. [1 ]
Thompson, R. Houston [1 ]
Leibovich, Bradley C. [1 ]
Boorjian, Stephen A. [1 ]
Sharma, Vidit [1 ]
机构
[1] Mayo Clin, Dept Urol, 200 First St SW, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源
JOURNAL OF UROLOGY | 2024年 / 212卷 / 02期
关键词
kidney neoplasms; nephrectomy; renal cell carcinoma; POSTOPERATIVE PROGNOSTIC NOMOGRAM; ADJUVANT PEMBROLIZUMAB; RADICAL NEPHRECTOMY; PREDICTION; MANAGEMENT; RECURRENCE;
D O I
10.1097/JU.0000000000004030
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The AUA guidelines introduced a new risk group stratification system based primarily on tumor stage and grade to guide surveillance for patients treated surgically for localized renal cell carcinoma (RCC). We sought to evaluate the predictive ability of these risk groups using progression-free survival (PFS) and cancer-specific survival (CSS), and to compare their performance to that of our published institutional risk models. Materials and Methods: We queried our Nephrectomy Registry to identify adults treated with radical or partial nephrectomy for unilateral, M0, clear cell RCC, or papillary RCC from 1980 to 2012. The AUA stratification does not apply to other RCC subtypes as tumor grading for other RCC, such as chromophobe, is not routinely performed. PFS and CSS were estimated using the Kaplan-Meier method. Predictive abilities were evaluated using C indexes from Cox proportional hazards regression models. Results: A total of 3191 patients with clear cell RCC and 633 patients with papillary RCC were included. For patients with clear cell RCC, C indexes for the AUA risk groups and our model were 0.780 and 0.815, respectively (P < .001) for PFS, and 0.811 and 0.857, respectively (P < .001), for CSS. For patients with papillary RCC, C indexes for the AUA risk groups and our model were 0.775 and 0.751, respectively (P = .002) for PFS, and 0.830 and 0.803, respectively (P = .2) for CSS. Conclusions: The AUA stratification is a parsimonious system for categorizing RCC that provides C indexes of about 0.80 for PFS and CSS following surgery for localized clear cell and papillary RCC.
引用
收藏
页码:331 / 341
页数:11
相关论文
共 50 条
  • [31] Mayo Adhesive Probability Score Is Associated With Localized Renal Cell Carcinoma Progression-free Survival EDITORIAL COMMENT
    Chalfin, Heather
    Gorin, Michael A.
    Allaf, Mohamad E.
    UROLOGY, 2016, 89 : 61 - 61
  • [32] Comparison and validation of different risk models for papillary renal cell carcinoma
    Lin, Haiyue
    Sun, Qi
    Li, Zeyang
    Zheng, Jingmei
    Zhang, Xue
    Xiong, Ying
    Chen, Hao
    Hou, Yingyong
    Xi, Wei
    Lin, Jinglai
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 358.e1 - 358.e7
  • [33] External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma
    Ficarra, V
    Martignoni, G
    Lohse, C
    Novara, G
    Pea, M
    Cavalleri, S
    Artibani, W
    JOURNAL OF UROLOGY, 2006, 175 (04): : 1235 - 1239
  • [34] ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
    Brooks, Samira A.
    Brannon, A. Rose
    Parker, Joel S.
    Fisher, Jennifer C.
    Sen, Oishee
    Kattan, Michael W.
    Hakimi, A. Ari
    Hsieh, James J.
    Choueiri, Toni K.
    Tamboli, Pheroze
    Maranchie, Jodi K.
    Hinds, Peter
    Miller, C. Ryan
    Nielsen, Matthew E.
    Rathmell, W. Kimryn
    EUROPEAN UROLOGY, 2014, 66 (01) : 77 - 84
  • [35] Risk of postoperative recurrence and prediction of drug response in localized clear cell renal cell carcinoma
    Ichiyanagi, Osamu
    Naito, Sei
    Ito, Hiromi
    Narisawa, Takafumi
    Yagi, Mayu
    Takai, Yuki
    Kanno, Hidenori
    Tsuchiya, Norihiko
    CANCER SCIENCE, 2024, 115 : 1409 - 1409
  • [36] Geriatric specificities of localized renal cell carcinoma
    Mongiat-Artus, P.
    Paillaud, E.
    Caillet, P.
    Albrand, G.
    Neuzillet, Y.
    PROGRES EN UROLOGIE, 2019, 29 (14): : 865 - 873
  • [37] Localized Renal Cell Carcinoma Management: An Update
    Heldwein, Flavio L.
    McCullough, T. Casey
    Souto, Carlos A. V.
    Galiano, Marc
    Barret, Eric
    INTERNATIONAL BRAZ J UROL, 2008, 34 (06): : 676 - 689
  • [38] Reply to Editorial Comment on "Evaluation of American Urological Association Renal Cell Carcinoma Risk Groups for Chromophobe Renal Cell Carcinoma"
    Britton, Cameron J.
    Potretzke, Aaron M.
    UROLOGY, 2024, 194 : 145 - 145
  • [39] RENAL-CELL CARCINOMA, CLINIC AND CHEMOTHERAPY
    POSSINGER, K
    HARTENSTEIN, R
    EHRHART, H
    FORTSCHRITTE DER MEDIZIN, 1981, 99 (12) : 419 - 423
  • [40] Editorial Comment on: External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology
    Blute, Michael L.
    EUROPEAN UROLOGY, 2010, 57 (01) : 110 - 111